Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 8Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1

Interventions

Trastuzumab 12Paclitaxel 10Taxes 9Doxorubicin 7Cyclophosphamide 7Docetaxel 6Bevacizumab 6Lapatinib 5Filgrastim 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5Vorinostat 4tipifarnib 3pegfilgrastim 3cediranib 3Peripheral Blood Stem Cell Transplantation 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Carboplatin 3Capecitabine 3veliparib 2ixabepilone 2entinostat 2alvocidib 2Tamoxifen 2Radiotherapy 2Neoadjuvant Therapy 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms, Male × MK 2206 × Clear all
NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
28 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
60 enrolled
BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡